One concrete data point for the thread. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.
A narrower follow-up, since the general answer is now clear:
How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?
TirzTom said:A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.
There is a second half to this that has not been said yet. Relative and absolute effects need reading together. A 20% relative reduction on a high baseline risk is a large absolute benefit; the same relative figure on a low baseline risk is a small one, and press summaries almost always quote the relative number because it is bigger.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOP back with an update, since a thread like this is useless without one.
Update — I went back to the injectable. Not because the tablet did not work, but because the fasting window and my mornings were never going to agree.
Dr.GutHealth said:Relative and absolute effects need reading together.
No disagreement with Dr.GutHealth. One condition attached. Worth adding that the tablet is taken daily, so a missed dose costs far less than a missed weekly injection. That is a genuine advantage nobody lists.